Bhatia Hospital, Bombay Mutual Terrace, 534 Sandhurst Bridge, 3rd Floor, Mumbai 400007, India.
Diabetes Res Clin Pract. 2011 Dec;94(3):364-70. doi: 10.1016/j.diabres.2011.10.020.
To determine the effects on quality of life after starting insulin with, or switching to, insulin analogue therapies in the 24-week, prospective, non-interventional, observational A(1)chieve study conducted across four continents in people with type 2 diabetes.
Health-related quality of life (HRQoL) was assessed at baseline and at 24 weeks by the validated EQ-5D questionnaire (visual analogue score [VAS] and five dimensions) in 66,726 people who had started using basal insulin detemir, mealtime insulin aspart (with or without a basal insulin) or biphasic insulin aspart 30.
For the overall cohort, reported HRQoL increased significantly by 13.8 points from 63.4 points at baseline to 77.2 points at 24 weeks (p<0.001) (scale 1-100, 100=best health imaginable). Beginning or changing insulin was associated with a significant increase in HRQoL score (+15.0 points and +11.1 points, respectively), resulting in a similar score at 24 weeks in the two populations (77.8 and 75.9 points). Reported HRQoL also increased statistically significantly in people administering any insulin analogue regimen and across all regions, although there were some marked regional differences in reported HRQoL at baseline.
Compared with baseline scores, beginning insulin with, or switching to, insulin analogue therapies are associated with increased HRQoL.
在跨四大洲进行的 24 周、前瞻性、非干预性、观察性 A(1)chieve 研究中,观察起始或转换为胰岛素类似物治疗后 24 周对 2 型糖尿病患者生活质量的影响。
在 66726 名起始使用基础胰岛素地特胰岛素、餐时胰岛素(联合或不联合基础胰岛素)或双相胰岛素门冬 30 的患者中,使用经过验证的 EQ-5D 问卷(视觉模拟评分[VAS]和五个维度)评估健康相关生活质量(HRQoL),分别于基线和 24 周进行评估。
对于整个队列,报告的 HRQoL 从基线的 63.4 分显著增加了 13.8 分,达到 24 周的 77.2 分(p<0.001)(量表 1-100,100=想象中最佳健康状况)。起始或转换胰岛素与 HRQoL 评分显著增加(分别为+15.0 分和+11.1 分)有关,导致这两个人群在 24 周时的评分相似(77.8 分和 75.9 分)。在使用任何胰岛素类似物治疗的人群以及所有地区,报告的 HRQoL 也显著增加,尽管在基线时报告的 HRQoL 存在一些明显的地区差异。
与基线评分相比,起始胰岛素治疗或转换为胰岛素类似物治疗与 HRQoL 的提高相关。